Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study.
Complex intervention
Hepatocellular carcinoma
Selective internal radiation therapy
Standardization
Textbook outcome
Transarterial radioembolization
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
24
05
2022
accepted:
09
10
2022
pubmed:
26
10
2022
medline:
24
1
2023
entrez:
25
10
2022
Statut:
ppublish
Résumé
A textbook outcome (TO) is a composite indicator covering the entire intervention process in order to reflect the "ideal" intervention and be a surrogate for patient important outcomes. Selective internal radiation therapy (SIRT) is a complex multidisciplinary and multistep intervention facing the challenge of standardization. This expert opinion-based study aimed to define a TO for SIRT of hepatocellular carcinoma. This study involved two steps: (1) the steering committee (4 interventional radiologists) first developed an extensive list of possible relevant items reflecting an optimal SIRT intervention based on a literature review and (2) then conducted an international and multidisciplinary survey which resulted in the final TO. This survey was online, from February to July 2021, and consisted three consecutive rounds with predefined settings. Experts were identified by contacting senior authors of randomized trials, large observational studies, or studies on quality improvement in SIRT. This study was strictly academic. A total of 50 items were included in the first round of the survey. A total of 29/40 experts (73%) responded, including 23 interventional radiologists (79%), three nuclear medicine physicians (10%), two hepatologists, and one oncologist, from 11 countries spanning three continents. The final TO consisted 11 parameters across six domains ("pre-intervention workup," "tumor targeting and dosimetry," "intervention," "post- This multidimensional indicator is a comprehensive standardization tool, suitable for routine care, clinical round, and research.
Sections du résumé
BACKGROUND
A textbook outcome (TO) is a composite indicator covering the entire intervention process in order to reflect the "ideal" intervention and be a surrogate for patient important outcomes. Selective internal radiation therapy (SIRT) is a complex multidisciplinary and multistep intervention facing the challenge of standardization. This expert opinion-based study aimed to define a TO for SIRT of hepatocellular carcinoma.
METHODS
This study involved two steps: (1) the steering committee (4 interventional radiologists) first developed an extensive list of possible relevant items reflecting an optimal SIRT intervention based on a literature review and (2) then conducted an international and multidisciplinary survey which resulted in the final TO. This survey was online, from February to July 2021, and consisted three consecutive rounds with predefined settings. Experts were identified by contacting senior authors of randomized trials, large observational studies, or studies on quality improvement in SIRT. This study was strictly academic.
RESULTS
A total of 50 items were included in the first round of the survey. A total of 29/40 experts (73%) responded, including 23 interventional radiologists (79%), three nuclear medicine physicians (10%), two hepatologists, and one oncologist, from 11 countries spanning three continents. The final TO consisted 11 parameters across six domains ("pre-intervention workup," "tumor targeting and dosimetry," "intervention," "post-
CONCLUSIONS
This multidimensional indicator is a comprehensive standardization tool, suitable for routine care, clinical round, and research.
Identifiants
pubmed: 36282299
doi: 10.1007/s00259-022-06002-5
pii: 10.1007/s00259-022-06002-5
doi:
Substances chimiques
Yttrium Radioisotopes
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
921-928Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71:209-49.
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604.
doi: 10.1038/s41575-019-0186-y
Benson AB, D’Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, et al. NCCN guidelines insights: hepatobiliary cancers, version 2.2019: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2019;17:302–10.
doi: 10.6004/jnccn.2019.0019
Jelic S, Sotiropoulos GC. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v59-64. https://doi.org/10.1093/annonc/mdq166 .
doi: 10.1093/annonc/mdq166
Vogel A, Martinelli E, Cervantes A, Chau I, Daniele B, Llovet JM, et al. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32:801–5.
doi: 10.1016/j.annonc.2021.02.014
Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol. 2022;76(3):681–93. https://doi.org/10.1016/j.jhep.2021.11.018 .
Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology (Baltimore, MD). 2021;74:2342–52. https://doi.org/10.1002/hep.31819PMID-33739462 .
doi: 10.1002/hep.31819PMID-33739462
Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36:1913–21.
doi: 10.1200/JCO.2017.76.0892
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624–36. https://doi.org/10.1016/s1470-2045(17)30683-6 .
doi: 10.1016/s1470-2045(17)30683-6
Ricke J, Klümpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71:1164–74.
doi: 10.1016/j.jhep.2019.08.006
Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, Baere Td, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:17–29. https://doi.org/10.1016/s2468-1253(20)30290-9 .
doi: 10.1016/s2468-1253(20)30290-9
Kolfschoten NE, Kievit J, Gooiker GA, Van Leersum NJ, Snijders HS, Eddes EH, et al. Focusing on desired outcomes of care after colon cancer resections; hospital variations in ‘textbook outcome.’ Eur J Surg Oncol. 2013;39:156–63.
doi: 10.1016/j.ejso.2012.10.007
Merath K, Chen Q, Bagante F, Alexandrescu S, Marques HP, Aldrighetti L, et al. A multi-institutional international analysis of textbook outcomes among patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma. JAMA surgery. 2019;154:e190571-e.
Merath K, Chen Q, Bagante F, Beal E, Akgul O, Dillhoff M, et al. Textbook outcomes among Medicare patients undergoing hepatopancreatic surgery. Ann Surg. 2020;271:1116–23.
doi: 10.1097/SLA.0000000000003105
Karthaus EG, Lijftogt N, Busweiler LAD, Elsman BHP, Wouters MWJM, Vahl AC, et al. Textbook outcome: a composite measure for quality of elective aneurysm surgery. Ann Surg. 2017;266:898–904.
doi: 10.1097/SLA.0000000000002388
Hobeika C, Fuks D, Cauchy F, Goumard C, Gayet B, Laurent A, et al. Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers. J Hepatol. 2020;73:1100–8. https://doi.org/10.1016/j.jhep.2020.05.003PMID-32407812 .
doi: 10.1016/j.jhep.2020.05.003PMID-32407812
Hobeika C, Nault JC, Barbier L, Schwarz L, Lim C, Laurent A, et al. Quality of surgical care has a significant impact on the probability of cure for early stage HCC occurring on cirrhosis. Jhep Reports. 2020;2:100153. https://doi.org/10.1016/j.jhepr.2020.100153PMID-32995713 .
doi: 10.1016/j.jhepr.2020.100153PMID-32995713
Miyayama S, Yamashiro M, Hashimoto M, Hashimoto N, Ikuno M, Okumura K, et al. Identification of small hepatocellular carcinoma and tumor-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization. J Vasc Interv Radiol. 2013;24:501–8. https://doi.org/10.1016/j.jvir.2012.12.022 .
doi: 10.1016/j.jvir.2012.12.022
Hermann A-L, Dieudonné A, Ronot M, Sanchez M, Pereira H, Chatellier G, et al. Relationship of tumor radiation–absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90 Y in the SARAH study. Radiology. 2020:191606. https://doi.org/10.1148/radiol.2020191606 .
Allimant C, Kafrouni M, Delicque J, Ilonca D, Cassinotto C, Assenat E, et al. Tumor targeting and three-dimensional voxel-based dosimetry to predict tumor response, toxicity, and survival after yttrium-90 resin microsphere radioembolization in hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29(1662–70):e4.
Greatorex J, Dexter T. An accessible analytical approach for investigating what happens between the rounds of a Delphi study. J Adv Nurs. 2000;32:1016–24.
Gargon E, Williamson PR, Altman DG, Blazeby JM, Clarke M. The COMET Initiative database: progress and activities from 2011 to 2013. Trials. 2014;15:1–5.
doi: 10.1186/1745-6215-15-279
Chevance A, Tran V, Ravaud P. Improving the generalizability and credibility of core outcome sets (COSs) by a large and international participation of diverse stakeholders. J Clin Epidemiol. 2020;125:206–212.e1. https://doi.org/10.1016/j.jclinepi.2020.01.004 .
Grégory J, Créquit P, Vilgrain V, Boutron I, Ronot M. Published trials of TACE for HCC are often not registered and subject to outcome reporting bias. Jhep Reports. 2021;3:100196.
doi: 10.1016/j.jhepr.2020.100196
Gargon E, Williamson PR, Blazeby JM, Kirkham JJ. Improvement was needed in the standards of development for cancer core outcome sets. J Clin Epidemiol. 2019;112:36–44.
doi: 10.1016/j.jclinepi.2019.04.006
Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49:1682–99. https://doi.org/10.1007/s00259-021-05600-zPMID-35146577 .
doi: 10.1007/s00259-021-05600-zPMID-35146577
Salem R, Padia SA, Lam M, Bell J, Chiesa C, Fowers K, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46:1695–704. https://doi.org/10.1007/s00259-019-04340-5PMID-31098749 .
doi: 10.1007/s00259-019-04340-5PMID-31098749
Levillain H, Burghelea M, Derijckere ID, Guiot T, Gulyban A, Vanderlinden B, et al. Combined quality and dose-volume histograms for assessing the predictive value of 99mTc-MAA SPECT/CT simulation for personalizing radioembolization treatment in liver metastatic colorectal cancer. Ejnmmi Phys. 2020;7:75. https://doi.org/10.1186/s40658-020-00345-4PMID-33315160 .
doi: 10.1186/s40658-020-00345-4PMID-33315160